Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 337 (ICMT-DT, also known as LINC00337) is a long non-coding RNA located on chromosome 1 (1p36.31), classified as a divergent transcript. It does not encode a protein, but regulates gene expression through molecular interactions such as sponging microRNAs. Its elevated expression has been linked to increased cell proliferation, migration, invasion, and chemoresistance in multiple cancers, including breast, pancreatic, and esophageal cancer. Mechanistically, ICMT-DT/LINC00337 acts via ceRNA functions—for example, it can sequester miR-145, impairing suppression of oncogenic targets like FSCN1, resulting in enhanced tumor progression. ICMT-DT is notable as a prognostic biomarker for malignancy, but is not a conventional therapeutic target like a receptor or enzyme, and there are no approved drugs that directly modulate its activity.
Acts as a competitive endogenous RNA (ceRNA) by sponging microRNAs (e.g., miR-145, impairing its suppression of target genes such as FSCN1, thus facilitating oncogenic pathways); Modulates tumor-associated macrophage polarization (M2 phenotype)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 337 (ICMT-DT).